Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745651 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL20745058 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16816242 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16815686 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL20513851 | 0.75 | SMN1; SMN2 (0.64) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL23657556 | 0.74 | SMN1; SMN2 (0.52) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16815495 | 0.74 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16815276 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL16815718 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 | |
| SCHEMBL20745064 | 0.72 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2AMAPTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3668504-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SMN1; SMN2 609/4885KMT2A 1375/4885MAPT 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.